Skip to main content
EJNMMI Research

Table 3 Hb, WBC and Plt values on the treatment day and hematotoxicity measured 2 months after Lu-PSMA therapy

From: Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study

Number

Baseline Hb (g/dl)

CTC Hb

Baseline WBC (g/l)

CTC WBC

Baseline Plt (g/l)

CTC Plt

1

9.6

0

7.4

0

352

0

2

11

0

7.1

0

322

0

3

9.0

0

4.7

0

181

1

4

11.7

3

3.3

2

62

0

5

11.5

0

5.9

0

170

0

6

14.5

0

8.8

0

234

0

7

11.4

0

8.0

0

295

0

8

12.2

1

10.1

0

313

0

9

9.3

0

3.4

1

99

2

10

9.9

0

7.3

0

321

0

  1. Patient 4, 9 and 10 had received blood transfusion prior to therapy because of low Hb levels
  2. CTC common toxicity criteria 2 months after therapy, Hb hemoglobulin, PLt platelet, WBC white blood cells
Back to article page